People · Operator
Named in public records as an officer, director or promoter · active 2010–2010 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Discgenics, Inc. | — | Biotechnology | Seed | $5.7M | $81.7M | 2010 |
Christopher D. Duntsch, M.D., Ph.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher D. Duntsch, M.D., Ph.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| J. Flagg Flanagan | 1 | 4 |
| Robert M. Wynalek | 1 | 1 |
| Kevin T. Foley | 1 | 1 |
| Kevin T. Foley, M.D. | 1 | 1 |
| Mark S. Cohen | 1 | 1 |
| Mike A. Moffat | 1 | 1 |
| Greg A. Ziskind | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.